Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Katiuscia Bonezzi"'
Autor:
Katiuscia Bonezzi, Dorina Belotti, Brian J. North, Carmen Ghilardi, Patrizia Borsotti, Andrea Resovi, Paolo Ubezio, Antonella Riva, Raffaella Giavazzi, Eric Verdin, Giulia Taraboletti
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 14, Iss 9, Pp 846-854 (2012)
Taxanes are potent inhibitors of cell motility, a property implicated in their antiangiogenic and antimetastatic activity and unrelated to their antiproliferative effect. The molecular mechanism of this anti-motility activity is poorly understood. In
Externí odkaz:
https://doaj.org/article/324bba01ddad45f9bda06f2d628005cb
Autor:
Cristina Belgiovine, Roberta Frapolli, Katiuscia Bonezzi, Ilaria Chiodi, Francesco Favero, Maurizia Mello-Grand, Angelo P Dei Tos, Elena Giulotto, Giulia Taraboletti, Maurizio D'Incalci, Chiara Mondello
Publikováno v:
PLoS ONE, Vol 5, Iss 11, p e14154 (2010)
BackgroundMesenchymal and amoeboid movements are two important mechanisms adopted by cancer cells to invade the surrounding environment. Mesenchymal movement depends on extracellular matrix protease activity, amoeboid movement on the RhoA-dependent k
Externí odkaz:
https://doaj.org/article/ab26f552175c4a31926a567953d3f219
Autor:
Ilaria Chiodi, Chiara Mondello, Maurizio D'Incalci, Cristina Belgiovine, Katiuscia Bonezzi, Giulia Taraboletti, Roberta Frapolli, Giulio Chiesa
Publikováno v:
Oncology Letters. 12:767-771
Cancer cells use two major types of movement: Mesenchymal, which is typical of cells of mesenchymal origin and depends on matrix metalloproteinase (MMP) activity, and amoeboid, which is characteristic of cells with a rounded shape and relies on the a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fede507ac35f104c76f027834f64500c
https://doi.org/10.3892/ol.2016.4642
https://doi.org/10.3892/ol.2016.4642
Autor:
Roberta Frapolli, Raffaella Giavazzi, Paolo Ubezio, Maurizio D'Incalci, Patrizia Borsotti, Massimo Zucchetti, Federica Sala, Monique Zangarini, Kay Noel, Katiuscia Bonezzi, Esteban Cvitkovic, Giulia Taraboletti
Publikováno v:
Cancer Chemotherapy and Pharmacology. 72:879-887
OTX008 is a galectin-1-targeting compound, currently undergoing a phase I clinical trial. This study aimed at investigating OTX008 pharmacokinetics (PK) and antineoplastic activity.Pharmacokinetics and activity of OTX008 were analyzed in the human ov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9850dfc47cba39ae9f63e10c808148f
https://doi.org/10.1007/s00280-013-2270-2
https://doi.org/10.1007/s00280-013-2270-2
Autor:
Andrea Resovi, Raffaella Giavazzi, Patrizia Borsotti, Katiuscia Bonezzi, Paolo Ubezio, Antonella Riva, Giulia Taraboletti, Carmen Ghilardi, Eric Verdin, Brian J. North, Dorina Belotti
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 14, Iss 9, Pp 846-854 (2012)
Taxanes are potent inhibitors of cell motility, a property implicated in their antiangiogenic and antimetastatic activity and unrelated to their antiproliferative effect. The molecular mechanism of this anti-motility activity is poorly understood. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebaef412b46c0d1a27e7dcb11e3c9baa
http://www.sciencedirect.com/science/article/pii/S1476558612800881
http://www.sciencedirect.com/science/article/pii/S1476558612800881
Publikováno v:
Vascular Disruptive Agents for the Treatment of Cancer ISBN: 9781441966087
A growing body of preclinical and clinical evidence substantiates the feasibility of combining vascular disrupting agents (VDAs) and conventional anticancer therapies. The enhanced disease response to this combination is attributable to the respectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e19d6c94d3627aac6454dfa15a800557
https://doi.org/10.1007/978-1-4419-6609-4_4
https://doi.org/10.1007/978-1-4419-6609-4_4
Autor:
Giulia Taraboletti, Katiuscia Bonezzi
Publikováno v:
Recent Advances in Angiogenesis and Antiangiogenesis ISBN: 9781608050048
Angiogenesis-driven pathologies, including cancer, are sustained by a preponderance of angiogenic factors over endogenous inhibitors of new-vessel formation. Restoring this balance represents a logical therapeutic strategy to treat these pathologies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a44794f170eaeb76af582004b1066b2
https://doi.org/10.2174/978160805004810901010112
https://doi.org/10.2174/978160805004810901010112
Autor:
Raffaella Giavazzi, Katiuscia Bonezzi, Blue leaf A Cordes, Douglas S. Annis, Marco Presta, Marco Rusnati, Deane F. Mosher, Barbara Margosio, Domenico Ribatti, Giulia Taraboletti, Chiara Urbinati
Thrombospondin-1, an antiangiogenic matricellular protein, binds with high affinity to the angiogenic fibroblast growth factor-2, affecting its bioavailability and activity. The present work aimed at further locating the fibroblast growth factor-2 bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fb00640e25c0e911fb8d4a225466e2c
http://hdl.handle.net/11379/28538
http://hdl.handle.net/11379/28538
Autor:
Michele Martinelli, Katiuscia Bonezzi, Anderson J. Ryan, E Riccardi, Giulia Taraboletti, Roberta Frapolli, E Kuhn, Raffaella Giavazzi, Massimo Zucchetti
Publikováno v:
British Journal of Cancer
The clinical success of small-molecule vascular disrupting agents (VDAs) depends on their combination with conventional therapies. Scheduling and sequencing remain key issues in the design of VDA-chemotherapy combination treatments. This study examin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21fb0d060d4e2c6ebdd1963ca28563ba
https://pubmed.ncbi.nlm.nih.gov/17848949
https://pubmed.ncbi.nlm.nih.gov/17848949